PDCD1 and endometrial carcinoma: Using Nivolumab, an anti-PD-1 antibody therapy, the study observed therapeutic responses exclusively in CRC and endometrial carcinoma patients with POLE mutations, reporting a survival rate of 5.4 months [107].